Results update & stocks in news
TCS: The company has been recognized as a leader in AWS services in the US by Information Services Group (ISG).
Garware Technical Fibres: The net sales of the company increased by 32.8 per cent to Rs 335.4 crore in Q4FY21 as compared to Rs 252.6 crore in Q4FY20. Net profit after tax has increased by 49.1 per cent to Rs 53.2 crore in the quarter as against Rs 35.7 crore in the corresponding period of FY20.
Sun Pharma: The company reported net profit for Q4FY21 at Rs 894.15 crore, up by 124 per cent over Q4 last year. Sun Pharma has repaid debt of about US$ 580 million in FY21 compared to the debt as of March 31, 2020.
Capri Global Capital: The total assets under management stood at Rs 4850 crore in Q4FY21 as against Rs 4040 crore in Q4FY20. Its 75 per cent+ book constitutes MSME and affordable housing finance. MSME book grew by 23 per cent YoY to Rs 2510 crore. The AUM of affordable housing finance grew by 29 per cent YoY to Rs 1160 crore. The asset quality remained healthy with NNPA at 0.9 per cent in Q4FY21.
Greenlam Industries: The company's net revenue was reported at Rs 415.3, a growth of 28.2 per cent on a YoY basis. Laminate business revenues grew by 28.9 per cent on a YoY basis. EBITDA was reported at Rs 67.1 crore, a growth of 48.3 per cent on a YoY basis. Net Profit was reported at Rs 30.9 crore, a growth of 42.3 per cent on a YoY basis. This is after taking into account an exceptional loss of Rs 12.4 crore, which denotes the amount paid for settling outstanding entry tax disputes with the Rajasthan & Himachal Pradesh Commercial Tax Department.
Hester Biosciences: An MoU has been signed between Bharat Biotech International Limited and Gujarat COVID Vaccine Consortium (GCVC) towards contract manufacturing for the drug substance for COVAXIN®.
IndiGrid: Q4FY21 revenue and EBITDA are up by 39 per cent YoY and 37 per cent YoY, respectively. Q4FY21 distribution at Rs 3.10 per unit is up by 3.3 per cent YoY. The company's FY21 performance got catapulted by accretive acquisitions and robust operations. Its AUM surpasses Rs 20500 crore on the back of accretive acquisitions.
FDC Ltd: The company's Q4FY21 revenue was reported at Rs 235.15 crore, down by 8.23 per cent YoY while FY21 revenue stood at Rs 992.59 crore, down by 6.69 per cent YoY. The overall sales in the Indian market accounted for 75.54 per cent of total consolidated sales for the quarter. The anti-infective therapy market remained in lower demand in Q4FY21 & throughout FY21 and also had a negative impact on FDC’s sales in India.
Metropolis Healthcare: Q4FY21 PAT stood at Rs 61.3 crore as against Rs 15.5 crore in Q4FY20, resulting in a growth of 296 per cent YoY.
Punjab Chemicals & Crop Protection: Q4FY21 revenue stood at Rs 209.6 crore, marking a 96.3 per cent YoY growth. The robust trajectory continues with growth from the contract research & manufacturing services (CRAMS) segment.
Infibeam Avenues: The company signed a definitive agreement with Reliance Industries’ Jio Platforms Limited and its affiliates (JPL) to license, customise, maintain & access IAL’s Enterprise E-commerce Software & Payments Platform for their business use.